Literature DB >> 11158995

Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

A Stirrat1, M Gallagher, S A Douglas, E H Ohlstein, C Berry, A Kirk, M Richardson, M R MacLean.   

Abstract

The peptide human urotensin-II (hUT-II) and its receptor have recently been cloned. The vascular function of this peptide in humans, however, has yet to be determined. Vasoconstrictor and vasodilator responses to hUT-II were investigated in human small muscular pulmonary arteries [approximately 70 microm internal diameter (ID)] and human abdominal resistance arteries (approximately 200 microm ID). Vasodilator responses were investigated in endothelin-1 (3 nM) precontracted vessels and, in the small pulmonary vessels, compared with the known vasodilators adrenomedullin, sodium nitroprusside, and acetylcholine. In human small pulmonary arteries, hUT-II did not induce vasoconstriction but was a potent vasodilator [-log M concentration causing 50% of the maximum vasodilator effect (pIC(50)) 10.4 +/- 0.5; percentage of reduction in tone (E(max)) 81 +/- 8% (vs. 23 +/- 11% in time controls), n = 5]. The order of potency for vasodilation was human urotensin-II = adrenomedullin (pIC(50) 10.1 +/- 0.4, n = 6) > sodium nitroprusside (pIC(50) 7.4 +/- 0.2, n = 6) = acetylcholine (pIC(50) 6.8 +/- 0.3, n = 6). In human abdominal arteries, hUT-II did not induce vasoconstriction but was a potent vasodilator [pIC(50) 10.3 +/- 0.7; E(max) 96 +/- 8% (vs. 43 +/- 16% in time controls), n = 4]. This is the first report that hUT-II is a potent vasodilator but not a vasoconstrictor of human small pulmonary arteries and systemic resistance arteries.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158995     DOI: 10.1152/ajpheart.2001.280.2.H925

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  29 in total

1.  Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.

Authors:  Christophe D Proulx; May Simaan; Emanuel Escher; Stéphane A Laporte; Gaétan Guillemette; Richard Leduc
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

2.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

3.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

4.  Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.

Authors:  Ana Patrícia Fontes-Sousa; Carmen Brás-Silva; Ana Luísa Pires; Daniela Monteiro-Sousa; Adelino F Leite-Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-14       Impact factor: 3.000

Review 5.  Essential hypertension and oxidative stress: New insights.

Authors:  Jaime González; Nicolás Valls; Roberto Brito; Ramón Rodrigo
Journal:  World J Cardiol       Date:  2014-06-26

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 7.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

8.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

Authors:  R T Bennett; R D Jones; A H Morice; C F C Smith; M E Cowen
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

9.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.

Authors:  Joseph Cheriyan; Timothy J Burton; Timothy J Bradley; Sharon M L Wallace; Kaisa M Mäki-Petäjä; Isla S Mackenzie; Carmel M McEniery; John Brown; Ian B Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.